Welcome to our dedicated page for NeOnc Technologies Holdings SEC filings (Ticker: NTHI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NeOnc Technologies Holdings, Inc. (NTHI) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures as a Nasdaq-listed issuer focused on central nervous system therapeutics. NeOnc’s filings, including Forms 8‑K and its registration statement on Form S‑1, provide structured insight into its CNS oncology pipeline, corporate transactions and capital structure.
Through recent 8‑K filings, NeOnc has furnished press releases and supporting materials describing updated Phase 1/2a and Phase 2a clinical results for intranasal NEO100 in recurrent WHO Grade III/IV IDH1‑mutant astrocytoma, including radiographic response data, progression-free survival and long-term survival metrics, as well as safety observations. Other 8‑K reports outline U.S. Food and Drug Administration authorization to proceed with Phase IIa/IIb development of NEO212, a bio-conjugated chemotherapy candidate for primary and metastatic brain tumors.
Filings also detail material agreements and strategic initiatives, such as a Master Services Agreement with Insights Pharmaceutical Research LLC (IROS) to conduct multi-site clinical trials in the United Arab Emirates, the formation and role of the NuroMENA subsidiary, share exchange transactions, and acquisitions of entities like JandB Holdings, LLC. Additional disclosures cover executive appointments, equity incentive awards, bridge loans, lines of credit and other financing arrangements that support NeOnc’s clinical programs.
On Stock Titan, these filings are supplemented with AI-powered summaries that explain the significance of each document in accessible language. Users can quickly understand key points from lengthy registration statements, 8‑K event descriptions and related exhibits, helping them interpret how clinical data updates, regulatory decisions, financing structures and governance changes may relate to NTHI’s CNS oncology strategy. Real-time updates from EDGAR ensure that new NeOnc filings are incorporated as they become available, enabling efficient review of the company’s ongoing reporting history.
NeOnc Technologies Holdings used this report to share first quarter 2026 results and progress in its brain cancer programs. For the quarter ended March 31, 2026, GAAP net loss was $8.8 million, and non-GAAP normalized cash operating expenses were $6.1 million.
Clinically, the company completed Phase 1 dose escalation for NEO212 and set 610 mg as the recommended Phase 2 dose, while its Phase 2a NEO100 study moves toward an interim readout supported by previously reported 24% radiographic remission and 44% six‑month progression-free survival. NeOnc also arranged a $10 million PIPE financing led by Cinctive Capital and noted an open‑market insider share purchase of more than $500,000.
NEONC Technologies Holdings, Inc. Schedule 13G reports that Cinctive Capital Management LP, Cinctive GP LLC and principals Richard H. Schimel and Lawrence J. Sapanski may each be deemed beneficial owners of 2,483,980 shares of Common Stock as of March 31, 2026.
The 2,483,980 figure consists of 1,425,526 shares of Common Stock and 1,058,454 shares issuable upon exercise of Warrants, subject to a 9.99% ownership blocker. The filing cites 23,806,216 shares outstanding as of March 30, 2026 used to calculate the reported approximately 9.99% ownership percentage. A Joint Filing Agreement is included.
NeOnc Technologies Holdings reported a larger first-quarter net loss while highlighting serious liquidity risks. For the three months ended March 31, 2026, the company generated no revenue and recorded a net loss of $8.8 million, compared with a $32.3 million loss a year earlier. Cash and cash equivalents were just $138,601 against total liabilities of $16.6 million, leaving a stockholders’ deficit of $13.2 million. Management states that existing capital is not sufficient to fund operations for one year from the financial statement issuance date and that this raises substantial doubt about NeOnc’s ability to continue as a going concern. To support operations, the company relied on equity financing, including a January 2026 private placement that brought in about $13.1 million of gross proceeds and sales under an equity purchase agreement.
NeOnc Technologies Holdings, Inc. filed an amendment to its annual report to add detailed Part III information on leadership, compensation, ownership, related-party dealings, and auditor fees for the year ended December 31, 2025. The filing describes a board with multiple independent directors, formal audit and compensation oversight, and a Code of Ethics and Insider Trading Policy. It outlines executive employment agreements, severance terms, and significant restricted stock grants under the 2023 Incentive Stock Plan, which reserves 4,764,507 shares. As of May 4, 2026, 25,285,530 common shares were outstanding and non‑affiliate equity market value was about $67.9 million.
NEONC Technologies Holdings president Amir F. Heshmatpour reported an open-market purchase of 10,000 shares of Common Stock at $4.1592 per share. After this buy, he directly holds 3,072,000 shares. The filing also lists additional indirect holdings through AFH Holdings & Advisory, LLC, KIG LLC, and HCWG LLC.
Certain shares are held by family members and LLCs, where he disclaims beneficial ownership except for any pecuniary interest described in the footnotes. Overall, this is a relatively small purchase compared with his multi‑million‑share aggregate stake.
NEONC Technologies Holdings, Inc. president and director Amir F. Heshmatpour reported an open-market purchase of 10,000 shares of common stock at $4.518 per share. Following this trade, his direct holdings total 3,062,000 shares of NTHI common stock.
The filing also lists significant indirect holdings, including shares held through AFH Holdings & Advisory, LLC, HCWG LLC, KIG LLC, and certain family members. The report notes that Heshmatpour disclaims beneficial ownership of some of these indirectly held shares except for any pecuniary interest.
NEONC TECHNOLOGIES HOLDINGS, INC. Chief Clinical Officer Yousha Neman-Ebrahim bought 500 shares of Common Stock in an open-market purchase at $4.88 per share. After this transaction, the executive directly owns 134,760 shares, so the new purchase represents a small addition to an already sizable position.
NEONC Technologies Holdings CFO Garnett Keithly reported an open-market purchase of 300 shares of common stock at $5.38 per share on April 15, 2025. Following this transaction, he directly holds 241,200 common shares.
Separately, the filing lists an indirect holding of 44,053 common shares owned by HCWG LLC. Keithly is a beneficial owner of these shares through his role as sole member of The Hilkiah Group LLC, which holds a 4.3% interest in HCWG LLC.
NeOnc Technologies Holdings, Inc. is raising capital through a series of private placements of common stock and five-year warrants. Across four Securities Purchase Agreements, the company has agreed to issue shares at $7.20 per share with accompanying warrants exercisable at $9.00 per share.
The latest, fourth agreement dated April 20, 2026 covers up to 406,694 shares and related warrants, with an initial closing of 277,777 shares and 277,777 warrants for approximately $2 million. Earlier agreements in January, February and March 2026 included multiple closings with institutional and other investors.
The company intends to use the net proceeds to fund NEO216 preclinical trials. The securities were issued under an exemption from registration provided by Section 4(a)(2) of the Securities Act, and NeOnc will file a resale registration statement for the shares and warrant shares within ten days of the initial closing under the fourth agreement.
Neonc Technologies Holdings, Inc. president Amir F. Heshmatpour reported an open-market purchase of 10,000 shares of common stock at $4.90 per share. The trade on April 23, 2026 increased his direct holdings to 3,052,000 shares.
He also reports indirect ownership interests, including 3,714,020 shares held by AFH Holdings & Advisory, LLC, 550,000 shares held by KIG LLC, and 256,120 shares representing his proportionate interest in HCWG LLC, with certain family and spousal holdings subject to beneficial ownership disclaimers.